New trial readouts can drive sentiment and near-term momentum, and the piece reinforces positive market expectations via a price-target increase and upbeat pipeline commentary; however it’s early-stage (Phase 1), limiting long-term certainty.
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge Rameen Kasana Thu, June 18, 2026 at 10:08 AM GMT+2 2 min read LLY Eli Lilly and Company (NYSE: LLY ) is among the stocks with the best earnings growth for the next 3 years . On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study.
The study showed that an investigational type II JAK2 inhibitor delivered an “encouraging” safety profile, demonstrating clinical activity in patients living with myelofibrosis who have failed a type I JAK2 inhibitor. The therapy is aimed at selectively binding the type II conformation of the JAK2 kinase, thus providing improved efficacy over current solutions. It will also offer a new option for patients who develop resistance to type I JAK2 inhibitors.
This addition follows the completion of the acquisition. Jim Cramer Reveals AbbVie's (ABBV) "Good Stuff" Copyright: kadmy / 123RF Stock Photo Earlier on June 9, Jefferies lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and reiterated a Buy rating. This comes after the company reported full data from retatrutide’s TRIUMPH-1 obesity study and TRANSCEND-T2D-1 study.
Despite some safety concerns, which the firm believes are manageable, the retatrutide’s overall profile “will be difficult to beat,” the firm said. Indeed, LLY is among the stocks with the best earnings growth for the next 3 years. Eli Lilly and Company (NYSE:LLY) is an Indiana-based company specializing in human pharmaceutical products.
Founded in 1876, the company offers products for cardiometabolic health, oncology, immunology, and migraine prevention. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News .
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →